期刊文献+

骨形态发生蛋白2在人骨不连组织中的表达及其临床意义 被引量:2

Expression of bone morphogenetic protein 2 in human nonunion tissue and the clinical significance
下载PDF
导出
摘要 目的:探讨肥大性骨不连组织与萎缩性骨不连组织在成骨潜能上的差异,进一步指导骨不连的治疗。方法:收集2010年10月至2014年3月入住中南大学湘雅二医院骨科的骨不连患者骨不连处组织40例,按照骨不连性质分为肥大性骨不连组(n=20)、萎缩性骨不连组(n=20);按照不同年龄段分为20~35岁年龄组(n=18)、36~50岁年龄组(n=18)、>50岁年龄组(n=4);按照骨不连时间分为9~12个月组(n=21)、13~24个月组(n=14)和>24个月组(n=5)。利用免疫组织化学SP二步法及IPP6.0病理图像分析软件对骨不连组织中骨形态发生蛋白-2(bone morphogenetic protein-2,BMP-2)的表达进行半定量分析,测定其平均吸光度值。结果:肥大性骨不连组BMP-2平均吸光度值为0.1540±0.0408,萎缩性骨不连组BMP-2平均吸光度值为0.1372±0.0372,两组标本BMP-2平均吸光度值差异无明显统计学意义(P>0.05)。20~35岁年龄组BMP-2平均吸光度值为0.1477±0.0379,36~50岁年龄组BMP-2平均吸光度值为0.1419±0.0399,>50岁年龄组BMP-2平均吸光度值为0.1456±0.0595,三组年龄段标本间BMP-2平均吸光度值差异无明显统计学意义(P>0.05)。在三组不同骨不连时间中,9~12个月组BMP-2的平均吸光度值为0.1449±0.0366,13~24个月组BMP-2的平均吸光度值为0.1472±0.0400,>24个月组BMP-2的平均吸光度值为0.1445±0.0541,三组不同骨不连时间标本之间BMP-2平均吸光度值差异亦无明显统计学意义(P>0.05)。结论:肥大性骨不连组织和萎缩性骨不连组织在成骨潜能上无显著性差异。 Objective:To explore the difference of bone formation potential between hypertrophic nonunion tissue and atrophic nonunion tissue,which may be beneficial to nonunion therapy.Methods:From October 2010 to March 2014,40 nonunion tissue samples were collected in Department of Orthopedics,Second Xiangya Hospital.The samples were divided into a hypertrophic nonunion group(n=20) and an atrophic nonunion group(n=20) according to nonunion character;or a 20 to 35 years old group(n=18),a 36 to 50 years old group(n=18),a more than 50 years old group(n=4) according to different ages;or a 9-12 months group(n=21),13-24 months group(n=14) and a more than 24 months group(n=5) according to different nonunion time.Semi-quantification was performed by SP immunohistochemical method and IPP6.0 was used to analyze the expression of bone morphogenetic protein-2(BMP-2) through measuring the mean optical density.Results:The mean optical density of BMP-2 was 0.1540±0.0408 in hypertrophic nonunion tissue,0.1372±0.0372 in atrophic nonunion tissue,there was no significant difference between the 2groups(P>0.05).The mean optical density of BMP-2 was 0.1477±0.0379 in the 20 to 35 years old group,0.1419±0.0399 in the 35 to 50 years old group,0.1456±0.0595 in the more than 50 years old group,there was no significant difference among the three groups(P>0.05).The mean optical density of BMP-2 was 0.1449±0.0366 in the 9-12 months group,0.1472±0.0400 in the13-24 months group,0.1445±0.0541 in the more than 24 months group,there was no significant difference among the 3 groups(P>0.05).Conclusion:The present results suggest that the hypertrophic nonunion tissue share similar osteogenic potential with the atrophic nonunion tissue.
出处 《中南大学学报(医学版)》 CAS CSCD 北大核心 2014年第10期1023-1028,共6页 Journal of Central South University :Medical Science
基金 国家自然科学基金(81000821) 教育部博士点基金(新教师类)(20100162120062) 湖南省科技计划项目(2013FJ6001)~~
关键词 骨不连 骨不连组织 骨形态发生蛋白-2 免疫组织化学 nonunion nonunion tissue bone morphogenetic protein-2 immunohistochemistry
  • 相关文献

参考文献8

  • 1Augusto Sarmiento,William E. Burkhalter,Loren L. Latta.Functional bracing in the treatment of delayed union and nonunion of the tibia[J].International Orthopaedics.2003(1)
  • 2D. Chen,M. A. Harris,G. Rossini,C. R. Dunstan,S. L. Dallas,J. Q. Feng,G. R. Mundy,S. E. Harris.Bone Morphogenetic Protein 2 (BMP-2) Enhances BMP-3, BMP-4, and Bone Cell Differentiation Marker Gene Expression During the Induction of Mineralized Bone Matrix Formation in Culturesof Fetal Rat Calvarial Osteoblasts[J].Calcified Tissue International.1997(3)
  • 3Hossein Hosseinkhani,Mohsen Hosseinkhani,Ali Khademhosseini,Hisatoshi Kobayashi.Bone regeneration through controlled release of bone morphogenetic protein-2 from 3-D tissue engineered nano-scaffold[J]. Journal of Controlled Release . 2006 (3)
  • 4Zhaowei Lin,Jiang?Sheng Wang,Lijun Lin,Jingwen Zhang,Yunlong Liu,Ming Shuai,Qi Li.Effects of BMP2 and VEGF165 on the osteogenic differentiation of ratbone marrow?derived mesenchymal stem cells[J].Experimental and Therapeutic Medicine.2014(3)
  • 5Khaled A. Hussein,Ibrahim E. Zakhary,Dana Hailat,Rami Elrefai,Mohamed Sharawy,Mohammed E. Elsalanty.Delayed Versus Immediate Reconstruction of Mandibular Segmental Defects Using Recombinant Human Bone Morphogenetic Protein 2/Absorbable Collagen Sponge[J].Journal of Oral and Maxillofacial Surgery.2013(6)
  • 6Josh E Shroeder,Rami Mosheiff,Amal Khoury,Meir Liebergall,Yoram A Weil.The Outcome of Closed, Intramedullary Exchange Nailing With Reamed Insertion in the Treatment of Femoral Shaft Nonunions[J].Journal of Orthopaedic Trauma.2009(9)
  • 7MinaOkamoto,JunkoMurai,HidekiYoshikawa,NoriyukiTsumaki.Bone Morphogenetic Proteins in Bone Stimulate Osteoclasts and Osteoblasts During Bone Development[J].J Bone Miner Res.2009(7)
  • 8韩昕光,毕郑钢,王东奎,杨成林,刘伟.骨不连接区成骨活性的实验研究[J].中华创伤骨科杂志,2009,11(1):45-50. 被引量:12

二级参考文献17

  • 1Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature, 2003, 423: 349-355.
  • 2Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003, 423: 337-342.
  • 3Nussenbaum B, Teknos TN, Chepeha DB. Tissue engineering: the current status of this futuristie modality in head neck reconstruction. Curt Opin Otolaryngol Head Neck Surg, 2004, 12: 311-315.
  • 4Chen D, Harris MA, Rossini G, et al. Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif Tissue Int, 1997, 60: 283-290.
  • 5Okamoto M, Mural J, Yoshikawa H, et al. Bone morphogenetic protelns in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res, 2006, 21: 1022-1033.
  • 6Hosseinkhani H, Hosseinkhani M, Khademhosseini A, et al. Bone regeneration through controlled release of bone morphogenetic prorein-2 from 3-D tissue engineered nano-scaffold. J Control Release, 2007, 117: 380-386.
  • 7Laine P, Reunanen N, Ravanti L, et al. Activation of extracellular signal-regulated protein kinasel, 2 results in down-regulation of decorin expression in fibrohlasts. Biochem J, 2000, 349 (Pt 1): 19-25.
  • 8Douglas T, Heinemann S, Bierbaum S, et al. Fibrillogenesis of collagen types Ⅰ, Ⅱ, and Ⅲ with small leucine-rich proteoglycans decorin and biglycan. Biomacromolecules, 2006, 7: 2388-2393.
  • 9Nakamura N, Hart DA, Boorman RS, et al. Decorin antisense gene therapy improves functional healing of early rabbit ligament scar with enhanced collagen fibrillogenesis in vivo. J Orthop Res, 2000, 18: 517 -523.
  • 10Hoshi K, Kemmotsu S, Takeuchi Y, et al. The primary calcification in bones follows removal of decorin and fusion of collagen fibrils. J Bone Miner Res, 1999, 14: 273-280.

共引文献12

同被引文献47

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部